PMID- 27383774
OWN - NLM
STAT- MEDLINE
DCOM- 20180116
LR  - 20180116
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 25
IP  - 9
DP  - 2016 Sep
TI  - Risk of Lung Cancer Associated with COPD Phenotype Based on Quantitative Image
      Analysis.
PG  - 1341-7
LID - 10.1158/1055-9965.EPI-16-0176 [doi]
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a risk factor for
      lung cancer. This study evaluates alternative measures of COPD based on
      spirometry and quantitative image analysis to better define a phenotype that
      predicts lung cancer risk. METHODS: A total of 341 lung cancer cases and 752
      volunteer controls, ages 21 to 89 years, participated in a structured interview, 
      standardized CT scan, and spirometry. Logistic regression, adjusted for age,
      race, gender, pack-years, and inspiratory and expiratory total lung volume, was
      used to estimate the odds of lung cancer associated with FEV1/FVC, percent voxels
      less than -950 Hounsfield units on the inspiratory scan (HUI) and percent voxels 
      less than -856 HU on expiratory scan (HUE). RESULTS: The odds of lung cancer were
      increased 1.4- to 3.1-fold among those with COPD compared with those without,
      regardless of assessment method; however, in multivariable modeling, only percent
      voxels <-856 HUE as a continuous measure of air trapping [OR = 1.04; 95%
      confidence interval (CI), 1.03-1.06] and FEV1/FVC < 0.70 (OR = 1.71; 95% CI,
      1.21-2.41) were independent predictors of lung cancer risk. Nearly 10% of lung
      cancer cases were negative on all objective measures of COPD. CONCLUSION:
      Measures of air trapping using quantitative imaging, in addition to FEV1/FVC, can
      identify individuals at high risk of lung cancer and should be considered as
      supplementary measures at the time of screening for lung cancer. IMPACT:
      Quantitative measures of air trapping based on imaging provide additional
      information for the identification of high-risk groups who might benefit the most
      from lung cancer screening. Cancer Epidemiol Biomarkers Prev; 25(9); 1341-7.
      (c)2016 AACR.
CI  - (c)2016 American Association for Cancer Research.
FAU - Schwartz, Ann G
AU  - Schwartz AG
AD  - Karmanos Cancer Institute, Detroit, Michigan. Department of Oncology, Wayne State
      University School of Medicine, Detroit, Michigan. schwarta@karmanos.org.
FAU - Lusk, Christine M
AU  - Lusk CM
AD  - Karmanos Cancer Institute, Detroit, Michigan. Department of Oncology, Wayne State
      University School of Medicine, Detroit, Michigan.
FAU - Wenzlaff, Angela S
AU  - Wenzlaff AS
AD  - Karmanos Cancer Institute, Detroit, Michigan. Department of Oncology, Wayne State
      University School of Medicine, Detroit, Michigan.
FAU - Watza, Donovan
AU  - Watza D
AD  - Department of Oncology, Wayne State University School of Medicine, Detroit,
      Michigan.
FAU - Pandolfi, Stephanie
AU  - Pandolfi S
AD  - Department of Oncology, Wayne State University School of Medicine, Detroit,
      Michigan.
FAU - Mantha, Laura
AU  - Mantha L
AD  - Karmanos Cancer Institute, Detroit, Michigan.
FAU - Cote, Michele L
AU  - Cote ML
AD  - Karmanos Cancer Institute, Detroit, Michigan. Department of Oncology, Wayne State
      University School of Medicine, Detroit, Michigan.
FAU - Soubani, Ayman O
AU  - Soubani AO
AD  - Karmanos Cancer Institute, Detroit, Michigan. Department of Internal Medicine,
      Wayne State University School of Medicine, Detroit, Michigan.
FAU - Walworth, Garrett
AU  - Walworth G
AD  - Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.
FAU - Wozniak, Antoinette
AU  - Wozniak A
AD  - Karmanos Cancer Institute, Detroit, Michigan. Department of Oncology, Wayne State
      University School of Medicine, Detroit, Michigan.
FAU - Neslund-Dudas, Christine
AU  - Neslund-Dudas C
AD  - Department of Public Health Sciences, Henry Ford Health System, Detroit,
      Michigan. Josephine Ford Cancer Institute, Henry Ford Health System, Detroit,
      Michigan.
FAU - Ardisana, Amy A
AU  - Ardisana AA
AD  - Department of Public Health Sciences, Henry Ford Health System, Detroit,
      Michigan. Josephine Ford Cancer Institute, Henry Ford Health System, Detroit,
      Michigan.
FAU - Flynn, Michael J
AU  - Flynn MJ
AD  - Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
      Department of Radiology, Henry Ford Health System, Detroit, Michigan.
FAU - Song, Thomas
AU  - Song T
AD  - Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
      Department of Radiology, Henry Ford Health System, Detroit, Michigan.
FAU - Spizarny, David L
AU  - Spizarny DL
AD  - Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
      Department of Radiology, Henry Ford Health System, Detroit, Michigan.
FAU - Kvale, Paul A
AU  - Kvale PA
AD  - Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
      Department of Pulmonary and Critical Care Medicine, Henry Ford Health System,
      Detroit, Michigan.
FAU - Chapman, Robert A
AU  - Chapman RA
AD  - Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
      Department of Hematology/Oncology, Henry Ford Health System, Detroit, Michigan.
FAU - Gadgeel, Shirish M
AU  - Gadgeel SM
AD  - Karmanos Cancer Institute, Detroit, Michigan. Department of Oncology, Wayne State
      University School of Medicine, Detroit, Michigan.
LA  - eng
GR  - R01 CA141769/CA/NCI NIH HHS/United States
GR  - HHSN261201300011C/RC/CCR NIH HHS/United States
GR  - P30 CA022453/CA/NCI NIH HHS/United States
GR  - HHSN261201300011I/CA/NCI NIH HHS/United States
GR  - HHSN261201000028C/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160706
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American
      Association for Cancer Research, cosponsored by the American Society of
      Preventive Oncology
JID - 9200608
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lung/diagnostic imaging
MH  - Lung Neoplasms/diagnostic imaging/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Prospective Studies
MH  - Pulmonary Disease, Chronic Obstructive/diagnostic imaging/*epidemiology
MH  - Respiratory Function Tests
MH  - Risk Factors
MH  - Smoking/adverse effects/epidemiology
MH  - Spirometry
MH  - Tomography, X-Ray Computed
MH  - Vital Capacity
PMC - PMC5010488
MID - NIHMS801274
COIS- Disclosures: For all of the authors, no conflict of interest disclosures were
      declared.
EDAT- 2016/07/08 06:00
MHDA- 2018/01/18 06:00
CRDT- 2016/07/08 06:00
PHST- 2016/02/24 00:00 [received]
PHST- 2016/05/31 00:00 [accepted]
PHST- 2016/07/08 06:00 [entrez]
PHST- 2016/07/08 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 1055-9965.EPI-16-0176 [pii]
AID - 10.1158/1055-9965.EPI-16-0176 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1341-7. doi:
      10.1158/1055-9965.EPI-16-0176. Epub 2016 Jul 6.